Judge denies states’ motion to postpone Medicaid work requirement
Federal judge denied 26 states’ request to postpone the implementation of Medicaid work requirements announced in June.
Read at source →Source
STAT News
Medicine, biotech, and health policy
Health · 283 articles · page 6 of 8 · fetched 14 minutes ago
STAT+: Rising oil prices can boost the cost of some medicines. One expert says it’s time to lower reliance on fossil fuels
Unitaid found the rising price of oil could boost the cost of a widely used HIV medicine it reviewed in a detailed…
Read at source →
STAT+: Pharmalittle: We’re reading about an FDA panel nixing a Duchenne drug, FTC suing Hims & Hers, and more
An FDA advisory panel concluded clinical data for a Capricor treatment for Duchenne muscular dystrophy did not provide…
Read at source →
AdSponsoredSiguimi
Pure chronological social — no algorithm
See who you follow, newest first. Free to join. Posts that stay visible — not buried by an algo.
Join siguimi.com →
Ebola outbreak nears milestone, while a vaccine remains months away
Medicaid work rules, FTC sues Hims, and more health news from Morning Rounds
Read at source →
STAT+: FDA expert committee votes in favor of Replimune’s melanoma treatment
STAT is live-blogging a meeting of FDA experts to review Replimune’s experimental melanoma drug, RP1.
Read at source →
Chronically ill people face confusion over new Medicaid work rules and ‘medically frail’ exemption
Patients, advocates, and experts fear the difficulty in documenting a frailty exemption to Medicaid work requirements…
Read at source →
Opinion: U.S. dependence on China is a national security risk
“China is overtly seeking to displace U.S. leadership across the innovative biopharmaceutical value chain,” write…
Read at source →
Opinion: Ten years after WHO recognition, mycetoma remains one of the world’s most neglected diseases
“The next 10 years of mycetoma care will determine whether it remains a story of neglect or becomes one of collective…
Read at source →
Is it safe to drink Red Bull and alcohol? Questionable research tied to energy drink giant has shaped policy
Studies tied to Red Bull helped block warning labels about drinking alcohol along with energy drinks. Independent…
Read at source →
NSF testing new Ph.D. model giving trainees academic and industry experience
Students working in fields eligible for NSF funding will be able to participate, including chemistry, engineering, and…
Read at source →
STAT+: Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx
Latigo Biotherapeutics published positive data for an acute-pain drug meant to rival a Vertex medicine already on the…
Read at source →
STAT+: Hims misled consumers and violated their privacy, FTC alleges in a lawsuit
The U.S. Federal Trade Commission sued telehealth company Hims & Hers alleging business practices that agency says…
Read at source →
STAT+: End of Medicare drug subsidy gives Democrats new attack line on rising out-of-pocket costs
The White House decision to end a Medicare drug subsidy plays into Democratic arguments ahead of the midterms.
Read at source →STAT+: Pharmalittle: We’re reading about a fugitive who became a biotech exec, a hospital suing Lilly, and more
The discovery that a fugitive had been working under an alias in the biotech industry prompted a question: How did he…
Read at source →
STAT+: Why benchmarking clinical LLMs from OpenEvidence, Doximity is complicated
In this edition of AI Prognosis: A conversation about benchmarking leading clinical chatbots, investor view on AI in…
Read at source →
Fauci invokes Fifth Amendment in declining to answer questions before Senate panel
At a highly anticipated Senate hearing, Anthony Fauci evoked his Fifth Amendment right to refuse to answer questions…
Read at source →
A neglected issue in pedestrian, biker deaths
Fauci's testimony, visa time limits for research students, and more health news from Morning Rounds
Read at source →
STAT+: FDA expert panel recommends against approval of Capricor’s Duchenne drug
STAT is live-blogging an FDA meeting on Capricor Therapeutics’ treatment for Duchenne muscular dystrophy, which has…
Read at source →
STAT+: Clinical chatbots are taking medicine by storm. Should doctors trust them?
As LLMs compete for doctors' attention, some developers say the science of benchmarking their AI tools for safety and…
Read at source →
STAT+: In the biotech industry, a most-wanted fugitive was long hiding in plain sight
Ronald Fischer, a most-wanted fugitive, was long hiding in the biotech industry in plain sight, and using an alias more…
Read at source →
Opinion: The VA could help America win the biotechnology race with China
“Together, HHS, the VA, and the DOD form a strong American innovation ecosystem — one that China and other competitors…
Read at source →
Opinion: Prolonged hospital stays can leave children isolated. It needs to change
“The effects of isolation extend far beyond children’s time in the hospital,” writes medical student Anna Tsioulias.
Read at source →
STAT+: American Diabetes Association, facing calls for resignations, asks for patience
An open letter to the board of the American Diabetes Association said the board had badly mishandled an incident at its…
Read at source →
Six key issues we’re watching at Fauci’s hearing
Sen. Rand Paul is forcing Fauci to appear before his Senate panel.
Read at source →
Visa time limits on foreign Ph.D. students and postdocs will harm U.S. science, experts warn
A Trump administration plan to limit visas for graduate student and postdocs to four years is fueling concerns that the…
Read at source →
STAT+: Bracing for another Fauci hearing
Plus: Democrats take on Trump over IVF, and Trump's White House releases a new science funding blueprint.
Read at source →
STAT+: GSK lays out plans to cut costs, pursue more late-stage drug trials
New GSK CEO Luke Miels outlined his strategy to help the company navigate a patent cliff and get on a path toward…
Read at source →
STAT+: FDA staff reiterate concerns about Replimune skin cancer treatment
Regulators at the FDA have reiterated concerns that Replimmune does not have adequate data to support an approval of…
Read at source →STAT+: Pharmalittle: We’re reading about FDA views on a Duchenne drug, GSK cost savings, and more
The FDA said a Capricor stem cell treatment for Duchenne muscular dystrophy did not meet a Phase 3 trial's objectives —…
Read at source →
STAT+: Three questions with Whoop’s new CMO
In this edition of STAT Health Tech: A chat with Whoop's new chief medical officer, an update on CMS health tech…
Read at source →
Anthony Fauci’s pandemic-era diary entries
New data on American substance use, concerns of a global HIV resurgence, and more health news from Morning Rounds
Read at source →
STAT+: Preliminary trial results suggest a path to a safer Alzheimer’s treatment
ProMIS Neurosciences is trying to design a safer amyloid-clearing drug for Alzheimer's. Early results suggest it might…
Read at source →
STAT+: CMS evaluates one year of health tech progress, announces eight new pledge categories
One year after launching the CMS Health Tech Ecosystem, officials convened in D.C. to celebrate the Trump…
Read at source →
STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
Biotech companies are racing to cure alpha-1 antitrypsin deficiency, AATD, fueling patent disputes, startup defections,…
Read at source →
Opinion: STAT+: Dementia finally has a business model
The big takeaway from the recent Alzheimer’s Association International Conference in London is an economic message:…
Read at source →
After PCOS became PMOS, there’s hope for new awareness among Black and Latina women
Growing awareness of a painful endocrine disorder now named PMOS is good news for women of color, who have high…
Read at source →